Studies have demonstrated enhanced renal CD40 in renal biopsy samples following allograft rejection, recurrent FSGS, and in lupus nephritis.13,14,21 Collectively, these data suggest therapeutic inhibition of renal CD40 could provide benefit in patients with kidney inflammation or glomerulonephritis. Here, CD40 is linked to lupus nephritis.